Clinical Trials: Current Studies
ACCRF has compiled a list of clinical trials for ACC patients with progressive disease to consider. This website is updated periodically, but may not list all the pertinent and available trials. Patients may search on their own for recruiting ACC clinical trials on the ClinicalTrials.gov website.
Not all clinical trials have similarly strong scientific rationales for why the drugs should be effective in ACC. The most promising studies will involve drugs that (1) target the known mechanisms of action in ACC, (2) demonstrate activity in preclinical models of ACC, and (3) have reports of clinical benefit in an ACC patient from a case study or Phase I clinical trial. To assist patients in appraising each clinical trial, we indicate whether the evidence supporting the scientific rationale is strong, solid or fair.
The table below lists Phase II clinical trials that are currently recruiting ACC patients:
Phase II Clinical Trials Recruiting ACC Patients (Updated August 2012)
Compound Target(s) Institution(s) Locations(s) Scientific Rationale Info Link Contact Dovitinib FGFR, VEGFR, PDGFR, CKIT Seoul National University Seoul, Korea Strong View Bhumsuk Keam, MD
Dovitinib FGFR, VEGFR, PDGFR, CKIT Ontario Clinical Oncology Group Hamilton, Ontario, Canada Strong View Susan Balca, RN
905-387-9495 ext 64439
FGFR, VEGFR, PDGFR, CKIT University of Virginia Charlottesville, VA, USA Strong View Snjezana Zaja-Milatovic
Sorafenib RAF, PDGFR, VEGFR, CKIT, RET Instituto Nazionale dei Tumori Milan, Italy Solid NA Lisa Licitra
Axitinib VEGFR, PDGFR, CKIT Memorial Sloan-Kettering New York, NY, USA Solid View Alan L. Ho, MD, PhD
(Suspended pending interim review)
AKT Memorial Sloan-Kettering New York, NY, USA Fair View Alan L. Ho, MD, PhD
Download Phase II Clinical Trials Recruiting ACC Patients (Updated November 2012)
It should be noted that the Phase II study of Vorinostat recently has completed enrollment and no longer is recruiting patients. The results have not been published, however, there were some promising Phase I results reported. Of five ACC patients enrolled, one had a partial response (tumor shrinkage of more than 30%) and the other four had stable disease.
Generally, patients prefer Phase II clinical trials to Phase I clinical trials because the toxicity of drugs in Phase II studies is well understood and the drugs are hypothesized to be particularly effective in the specific tumor type. In addition, Phase II studies may have less stringent eligibility criteria, more plentiful slots and a higher likelihood of insurance coverage. However, if a patient is unable or unwilling to travel to a Phase II study, there are Phase I studies that offer ACC patients access to promising drugs closer to home. In addition, the scientific rationale for the drug’s effectiveness in ACC is greater in some Phase I studies than in some Phase II studies.
The table below provides a list of selected Phase I clinical trials of drugs that inhibit molecular targets suspected of driving ACC. Links to the Wikipedia entry for the drug as well as the www.ClinicalTrials.gov description of the study are included.
Selected Phase I Clinical Trials (Updated August 2012)
Compound Target(s) Institution(s) Locations(s) Scientific Rationale Info Link Contact Dovitinib & Carboplatin or Cisplatin FGFR, VEGFR, PDGFR, CKIT Novartis New York, NY, USA Strong View Diana Aristizabal, CRN
Dovitinib FGFR, VEGFR, PDGFR, CKIT Novartis Multiple Sites in USA
(KS, MI, MN, NV, NJ)
Strong View Novartis Pharmaceuticals
AZD4547 FGFR, TRK AstraZeneca Multiple Sites in USA & Europe Solid View AstraZeneca Clinical Study Information
Download Selected Phase I Clinical Trials (Updated August 2012)